Food is Medicine Institute ’s Post

🚀Bioiatriki Healthcare Group labs are leveraging the power of indexor to ensure automated sample traceability from each branch to the central lab and to prioritize samples efficiently. Seeing firsthand how indexor is helping to transform their workflow is truly inspiring. We are proud to be a part of their journey!💪 #healthcare #laboratory #preanalytics #workflowoptimization #labautomation 

The landscape of global health product regulation is as diverse as it is challenging. At WeRegister by Enzytec, we specialize in turning these challenges into opportunities for growth and market access. Here’s what we’ve learned: Navigating Complexity: Every country has unique regulatory requirements, which can be a maze without the right guidance. Seizing Opportunities: Understanding these diverse regulations opens doors to multiple markets, enhancing the potential reach of your products. Strategic Planning: Our approach involves meticulous regulatory planning and strategy, ensuring not just compliance but also competitive advantage. Expert Guidance: With years of experience and a dedicated team, we provide insights and support that help bridge the gap between innovation and market presence. Let WeRegister simplify your journey through the complex terrain of global health product regulations. Embrace the opportunities that proper compliance can offer. #WeRegister #GlobalRegulation #HealthcareInnovation #RegulatoryChallenges #MarketAccess #HealthProductRegulation #GlobalHealth

This week I will be speaking at @DIA 2024 on the topic, “Breaking Boundaries: Overcoming Policy Crosstalk and Globalization Barriers to Foster Innovation” with Virginia Acha, Karen Noonan and Duane Schulthess. My comments will share a case study on taking a data-driven approach to strengthening the resiliency of the global medicines supply chain. Healthcare leaders share a desire to see innovation in treatments and prevention to address the many unmet needs of patients. Successful public policies must be based on data and science. In the case of supply chains, pharmacopeial standards, built on rigorous science and recognized by regulators globally, can provide a foundation for industry to operate with a higher degree of certainty and confidence. I hope you’re able to attend this DIA session, but I also invite you to read and share the latest @US Pharmacopeia Drug Shortages Report to encourage comprehensive action to strengthen global regulatory frameworks: https://lnkd.in/ehg7_fJv

BIO’s John Murphy III discusses the policy outlook for the year, with a focus on what it means for pricing and access to medicines at #BIOCEO24 Read more: https://lnkd.in/e7bExrwq

Articulating Added Value in Clinical Trials 🔬 At our clinics, we bring unmatched value to our clients and partners by maintaining complete control over our data and protocols. By owning and operating our clinics, we manage everything in-house—from protocol development by our science team to the execution of the trials. This minimizes external noise and variability, ensuring consistent and reliable data. Why does this matter? For functional foods, where effect sizes are often small, this consistency is crucial. By eliminating external variations, we ensure that the data remains consistent and reliable, ultimately providing our clients with more precise and beneficial trial outcomes. Trust in our process, rely on our results. #ClinicalTrials #FunctionalFoods #DataIntegrity #Research #Science #HealthcareInnovation #Atlantia

GLP-1's are getting a lot of renewed attention, for good reason. Better health outcomes, more affordable solutions, easier access to medications, and new delivery mechanisms. Nestle Vital Pursuits is on shelves now - where is your solution? Our model for how this all plays out over the next 3 years is worth baking into your strategic plans right now. This space is only going to get more interesting in the year(s) ahead. Kantar Consulting by Kantar J. Walker Smith Chris Carbone Nestlé

✨ A big thank you to the Medtech & Pharma Platform Association Annual Conference organizers for a fantastic day yesterday! I'm still processing all the valuable insights and will pull my notes together for a more in-depth post or blog in the coming days. For now, I'll share one key takeaway from an insightful exchange on determining the primary mode of action for combination products: 🔹 Be honest with yourself—are you genuinely uncertain or hoping for a particular answer? If it is genuinely borderline and you are indeed unsure: - Gather all the evidence, including test data (possibly animal studies) - Research relevant literature and identify any analogs to guide your thinking. - Engage regulatory bodies with this data before you get too far down the road. Their processes are all slightly different, but they have a way to answer a question like "Is this a medicinal product?" 🔹 The discussion featured a great panel with representatives from the EMA, FDA, Swissmedic, and Notified Bodies who shared stories of companies choosing the regulatory path they wanted only to have their product pulled from the market for being incorrectly classified or being forced to change paths at the eleventh hour—adding massive delays, extra effort, and significant cost. 🔹 Transparency is critical—share all relevant information with regulatory agencies to ensure a smoother conversation. They'll find it eventually, anyway! I look forward to diving deeper into more discussions from the conference soon! #CombinationProducts #RegulatoryAffairs #HealthcareInnovation #MPP2024

Had a wonderful time (as always) at the Oregon Bioscience Incubator and OTRADI monthly meetup last night. It was an especially informative session thanks to the panel discussion on Bioethics and Healthcare Decisions. A very engaged and thoughtful discussion with doctors Ruchi Thanawala, Murtaza Batla and William Hersh, MD. A key observation for me was the challenge practitioners face today as patients (admirably) do research to be better informed. In today's information age, practitioners encounter three main types of information when interacting with patients: * Information - True facts * Misinformation - Well-intentioned, but incorrect information * Disinformation - False facts spread on purpose I imagine it is especially challenging here in the U.S. where we are one of just two countries which allow direct-to-consumer drug ads on t.v. and other media. Do the people who see those ads critically evaluate them, comparing the improvements over a placebo? Add to that the misinformation and disinformation on the web and I can see it straining the ability of the provider to do the best for their patient. While the interplay of information trio is not unique to healthcare, its direct impact on patient health significantly heightens the challenge.

The rise of GLP-1 medications offers an exciting opportunity in the food industry, especially for developing supportive nutrition solutions. These medications have shown promise in weight management, but they come with side effects and challenges, such as weight regain after discontinuation. GLP-1s are here to stay and the only way to help people achieve lasting health will not be solely through pills or injections, but through healthy food and lifestyle....challenge accepted #foodasmedicine The NOURISH Movement Clareo

What two qualities are shared by US Pharmacopeia Expert Volunteers? USP Chief Science Officer and Council of Experts Chair Jaap Venema has the answer. Whether they’re from industry, academia, healthcare or regulatory agencies, hear ⤵️ how their passion for global #PublicHealth and openness to scientific dialogue make them assets to USP’s standards-setting body. Interested in sharing your passion? Find out how to apply to be a #USPExpertVolunteer and amplify your impact: Bit.ly/USPExpertVolunteer #ProudToBeUSP #PublicHealth